Stabilisation of kidney function (halting GFR decline for ≥12 months) is documented in approximately 50–60% of treated cohorts in early-stage CKD (stages 2–3). Advanced CKD (stages 4–5) shows lower response rates (30–40%), likely because fibrotic burden and residual nephron mass constrain regenerative potential. Reversal of established scarring is rare; the primary benefit is slowing progression toward dialysis or transplantation.
Trial databases document glomerular filtration rate (GFR) trajectories in CKD cohorts receiving placental or umbilical-cord MSCs. Representative phase II studies report GFR decline stabilisation or modest improvement (mean +3–8 mL/min/1.73m² over 12 months) in 45–60% of participants, versus continued decline in placebo arms. Proteinuria reduction (24-hour urine protein <50% baseline) occurs in 35–50% within 6 months. Histological fibrosis progression slows in kidney biopsy samples from responders. These outcomes remain investigational; no large pivotal trial has yet shaped clinical guidelines.
Am I a candidate? → · Chronic Kidney Disease: full overview → · Chronic Kidney Disease cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment